We propose to work with immunologists and vaccinologists to model the potential outcomes of "synchronized scheduling" to immunization coverage and protection, FP uptake, and growth monitoring success. We will also conduct research with immunization stakeholders in Africa to assess the acceptability of such a change. If both modeling and research are positive, we will hold a technical meeting to reach consensus on whether and how to move forward with a trial to formally assess the feasibility, acceptability and effectiveness of adjusted immunization schedules. If found to be feasible, acceptable and effective, this transformational new service delivery approach could be scalable at low cost. It is, however, a bold departure from current practice, and will be controversial within an immunization community concerned about stigma and reluctant to tamper with current schedules.

Sisu Global Health (previously, DIIME and CentriCycle) is creating a new standard of care for autologous blood transfusion. The Hemafuse is handheld, electricity-independent, locally-affordable tool designed be a safer, faster replacement. The device is syringe-like to manually suction and filter the blood for transfusion in a sterile, closed environment; decreasing risk of clots and of infection and promises to decrease the mortality of women.

Srikanth Mutnuri from BIRAC in India in collaboration with Willy Verstraete from Ghent University in Belgium, will aim to develop a financially affordable and simple-to-operate decentralized wastewater treatment system for a single household as well as for a gated community of 100 people (25 families) that will produce high quality effluent for safe disposal. The waste treatment system relies on electrochemical reactions and the production of chlorine, to manipulate the pH of the wastewater to destroy pathogens and helminthes.

We propose the use of a diagnostic technology for TB and HIV based in the use of a chimeric recombinant antibody obtained from a marine organism and modified by genetic engineering, which when added to a sample of blood from a patient infected by a certain disease will produce a visual reaction in the sample allowing the user to do a simple and fast screening of infected patients. This process does not require any kind of equipment and the user can use the test even without previous training. The use of this technology is aimed to be used at the point of care in communities without access to diagnostic labs where doctors or healthcare personnel will be able to perform these diagnostic tests to mothers and newborns for the control of Tuberculosis and HIV. This tool will improve the chances of both mother and child to be treated on time increasing their chances of recovering.